XML 69 R11.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenues | 12 Months Ended
--- | ---
Dec. 31, 2019
Revenue from Contract with Customer [Abstract] |
Revenues | Revenues Product Revenues Revenues by product are summarized as follows:
| For the Years Ended December 31,
| 2019 |  | 2018 |  | 2017
(In millions) | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 3,306.5 |  |  | $ | 1,126.2 |  |  | $ | 4,432.7 |  |  | $ | 3,253.2 |  |  | $ | 1,020.9 |  |  | $ | 4,274.1 |  |  | $ | 3,294.0 |  |  | $ | 920.0 |  |  | $ | 4,214.0 |
Interferon* | 1,426.6 |  |  | 675.2 |  |  | 2,101.8 |  |  | 1,668.3 |  |  | 694.7 |  |  | 2,363.0 |  |  | 1,889.1 |  |  | 756.7 |  |  | 2,645.8 |
TYSABRI | 1,041.8 |  |  | 850.4 |  |  | 1,892.2 |  |  | 1,025.0 |  |  | 839.0 |  |  | 1,864.0 |  |  | 1,113.8 |  |  | 859.3 |  |  | 1,973.1 |
VUMERITY | 5.5 |  |  | — |  |  | 5.5 |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
FAMPYRA | — |  |  | 97.1 |  |  | 97.1 |  |  | — |  |  | 92.7 |  |  | 92.7 |  |  | — |  |  | 91.6 |  |  | 91.6 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 1.4 |  |  | 1.4 |  |  | — |  |  | 52.7 |  |  | 52.7 |
Subtotal: MS Product Revenues | 5,780.4 |  |  | 2,748.9 |  |  | 8,529.3 |  |  | 5,946.5 |  |  | 2,648.7 |  |  | 8,595.2 |  |  | 6,296.9 |  |  | 2,680.3 |  |  | 8,977.2 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 933.4 |  |  | 1,163.6 |  |  | 2,097.0 |  |  | 854.0 |  |  | 870.2 |  |  | 1,724.2 |  |  | 657.0 |  |  | 226.7 |  |  | 883.7 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 486.2 |  |  | 486.2 |  |  | — |  |  | 485.2 |  |  | 485.2 |  |  | — |  |  | 370.8 |  |  | 370.8 |
IMRALDI | — |  |  | 184.0 |  |  | 184.0 |  |  | — |  |  | 16.7 |  |  | 16.7 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 68.1 |  |  | 68.1 |  |  | — |  |  | 43.2 |  |  | 43.2 |  |  | — |  |  | 9.0 |  |  | 9.0 |
Subtotal: Biosimilar product revenues | — |  |  | 738.3 |  |  | 738.3 |  |  | — |  |  | 545.1 |  |  | 545.1 |  |  | — |  |  | 379.8 |  |  | 379.8 |
Other: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 15.2 |  |  | 15.2 |  |  | — |  |  | 22.3 |  |  | 22.3 |  |  | — |  |  | 39.6 |  |  | 39.6 |
Hemophilia: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ELOCTATE | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 42.2 |  |  | 6.2 |  |  | 48.4 |
ALPROLIX | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 21.0 |  |  | 5.0 |  |  | 26.0 |
Subtotal: Hemophilia product revenues | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | 63.2 |  |  | 11.2 |  |  | 74.4 |
Total product revenues | $ | 6,713.8 |  |  | $ | 4,666.0 |  |  | $ | 11,379.8 |  |  | $ | 6,800.5 |  |  | $ | 4,086.3 |  |  | $ | 10,886.8 |  |  | $ | 7,017.1 |  |  | $ | 3,337.6 |  |  | $ | 10,354.7 |
*Interferon includes AVONEX and PLEGRIDY. We recognized revenues from two wholesalers accounting for 30% and 17% of gross product revenues in 2019, 32% and 18% of gross product revenues in 2018 and 34% and 21% of gross product revenues in 2017, respectively. As of December 31, 2019, two wholesale distributors individually accounted for approximately 24.1% and 13.9% of net accounts receivable associated with our product sales, as compared to 27.7% and 15.6% as of December 31, 2018, respectively. An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
2019 |  |  |  |  |  |  |
Beginning balance | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Current provisions relating to sales in current year | 666.2 |  |  | 3,011.5 |  |  | 20.9 |  |  | 3,698.6 |
Adjustments relating to prior years | 0.3 |  |  | (54.1 | ) |  | 5.5 |  |  | (48.3 | )
Payments/returns relating to sales in current year | (535.5 | ) |  | (2,242.9 | ) |  | (0.2 | ) |  | (2,778.6 | )
Payments/returns relating to sales in prior years | (127.7 | ) |  | (576.0 | ) |  | (20.4 | ) |  | (724.1 | )
Ending balance | $ | 131.1 |  |  | $ | 1,027.3 |  |  | $ | 40.5 |  |  | $ | 1,198.9 |
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
2018 |  |  |  |  |  |  |
Beginning balance | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
Current provisions relating to sales in current year | 679.3 |  |  | 2,686.7 |  |  | 23.1 |  |  | 3,389.1 |
Adjustments relating to prior years | (0.3 | ) |  | (10.0 | ) |  | (1.8 | ) |  | (12.1 | )
Payments/returns relating to sales in current year | (551.7 | ) |  | (1,887.6 | ) |  | (1.1 | ) |  | (2,440.4 | )
Payments/returns relating to sales in prior years | (109.1 | ) |  | (506.3 | ) |  | (31.5 | ) |  | (646.9 | )
Ending balance | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
2017 |  |  |  |  |  |  |
Beginning balance | $ | 71.6 |  |  | $ | 482.7 |  |  | $ | 51.2 |  |  | $ | 605.5 |
Current provisions relating to sales in current year | 583.0 |  |  | 2,307.4 |  |  | 26.9 |  |  | 2,917.3 |
Adjustments relating to prior years | (0.1 | ) |  | 15.0 |  |  | (8.9 | ) |  | 6.0 |
Payments/returns relating to sales in current year | (475.8 | ) |  | (1,756.9 | ) |  | (0.1 | ) |  | (2,232.8 | )
Payments/returns relating to sales in prior years | (69.1 | ) |  | (442.2 | ) |  | (23.1 | ) |  | (534.4 | )
Ending balance | $ | 109.6 |  |  | $ | 606.0 |  |  | $ | 46.0 |  |  | $ | 761.6 |
The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
| As of December 31,
(In millions) | 2019 |  | 2018
Reduction of accounts receivable | $ | 197.8 |  |  | $ | 176.6 |
Component of accrued expenses and other | 1,001.1 |  |  | 874.7 |
Total revenue-related reserves | $ | 1,198.9 |  |  | $ | 1,051.3 |
Revenues from Anti-CD20 Therapeutic Programs Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses | $ | 1,542.4 |  |  | $ | 1,431.9 |  |  | $ | 1,316.4 |
Other revenues from anti-CD20 therapeutic programs | 748.0 |  |  | 548.3 |  |  | 242.8 |
Total revenues from anti-CD20 therapeutic programs | $ | 2,290.4 |  |  | $ | 1,980.2 |  |  | $ | 1,559.2 |
Approximately 16%, 15% and 13% of our total revenues in 2019, 2018 and 2017, respectively, are derived from our collaboration arrangements with Genentech. For additional information on our collaboration arrangements with Genentech, please read Note 18, Collaborative and Other Relationships, to these consolidated financial statements. Other Revenues Other revenues are summarized as follows:
| For the Years Ended December 31,
(In millions) | 2019 |  | 2018 |  | 2017
Revenues from collaborative and other relationships: |  |  |  |  |
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc. | $ | — |  |  | $ | (8.6 | ) |  | $ | (16.9 | )
Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis | 106.2 |  |  | 96.4 |  |  | 42.7 |
Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX | — |  |  | — |  |  | 10.7 |
Other royalty and corporate revenues: |  |  |  |  |
Royalty | 17.0 |  |  | 38.7 |  |  | 69.8 |
Other corporate | 584.5 |  |  | 459.4 |  |  | 253.7 |
Total other revenues | $ | 707.7 |  |  | $ | 585.9 |  |  | $ | 360.0 |
Other corporate revenues primarily reflect amounts earned under contract manufacturing agreements with our strategic customers, including Bioverativ Inc. (Bioverativ). During the years ended December 31, 2019, 2018 and 2017, we recognized $383.2 million, $206.7 million and $64.8 million, respectively, in revenues under the manufacturing and supply agreement with Bioverativ entered into in connection with the spin-off of our hemophilia business. During the third quarter of 2019 we amended our agreement with a contract manufacturing customer. Under the amended agreement, we will license certain of our manufacturing-related intellectual property to the customer. We will be eligible to receive $500.0 million in a series of three payments. The first payment is due upon a regulatory achievement related to the customer's product manufactured using our manufacturing-related intellectual property, with subsequent payments payable upon the first and second anniversaries of the regulatory achievement. We expect the regulatory achievement to occur in 2020. If we earn this payment, we expect to allocate the consideration between the license for the manufacturing-related intellectual property and the manufacturing product supply services. For additional information on our collaboration arrangements with AbbVie Inc. (AbbVie) and Samsung Bioepis, please read Note 18, Collaborative and Other Relationships, to these consolidated financial statements.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration